Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2400-2407

  Wang, Zhiwei ^a   Li, Yiwei ^a   Kong, Dejuan ^a   Banerjee, Sanjeev ^a   Ahmad, Aamir ^a   Azmi, Asfar Sohail ^a   Ali, Shadan ^a   Abbruzzese, James L ^b   Gallick, Gary E ^b   Sarkarr, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; NOTCH RECEPTOR; NOTCH2 RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; VIMENTIN; ANTINEOPLASTIC ANTIMETABOLITE; CALCIUM BINDING PROTEIN; DEOXYCYTIDINE; DRUG DERIVATIVE; MEMBRANE PROTEIN; MESSENGER RNA; NOTCH2 PROTEIN, HUMAN; NOTCH4 PROTEIN, HUMAN; ONCOPROTEIN; SERRATE PROTEINS; SIGNAL PEPTIDE;

ARTICLE; CANCER CELL; CANCER STEM CELL; CELL ACTIVATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; MESENCHYME; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; CELL MOTION; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; MESODERM; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; CALCIUM-BINDING PROTEINS; CELL MOVEMENT; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MESODERM; NF-KAPPA B; PANCREATIC NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; RECEPTOR, NOTCH2; RECEPTORS, NOTCH; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 65549141305     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4312     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Stathopoulos GP, Androulakis N, Souglakos J, Stathopoulos j, Georgoulias V. Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res 2008;28:1303-8.
3. Kajiyama H, Shibata K, Terauchi M, et al. Chemo- resistance to paclitaxel induces epithelial-mesenchy- mal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int j Oncol 2007;31: 277-83.
4. Yang AD, Fan F, Camp ER, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006;12: 4147-53.
5. Hiscox S, Jiang WG, Obermeier K, et al. Tamoxifen resistance in MCF7 cells promotes EMT4ike behaviour and involves modulation of [V-catenin phosphorylation. Int j Cancer 2006;118:290-301.
6. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ("Iressa," ZD1839). Clin Exp Metastasis 2004;21:201-12.
7. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease, J Cell Mol Med 2008;12:374-90.
8. Kondo T. Brain cancer stem-like cells. Eur j Cancer 2006;42:1237-42.
9. Ponti D, Zaffaroni N, Capelli C, Daidone MG. Breast cancer stem cells: an overview. Eur J Cancer 2006;42: 1219-24.
10. Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma 2005;52:435-40.
11. Hugo H, Ackland ML, Blick T, et al. Epithelial- mesenchymal and mesenchymal-epithelial transitions in carcinoma progression.) Cell Physiol 2007;213:374-83.
12. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-kB and epithelial to mesenchymal transition of cancer, J Cell Biochem 2008;104:733-44.
13. Kong D, Wang Z, Sarkar SH, et al. Platelet-derived growth factor-D overexpression contributes to epitheli- al-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008;26:1425-35.
14. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidy- linositol 3′ kinase/AKT pathways. Oncogene 2005;24: 7443-54.
15. Peinado H, Olmeda D, Cano A, Snail, Zeh and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28.
16. Wu Y, Zhou BP. Mew insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 2008;40:643-50.
17. Rho JK, Choi Yj, Lee JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009;63:219-26.
18. Shah AN, Summy JM, Zhang j, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007;14:3629-37.
19. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-κB, vascular endothelial growth factor, and matrix metal loproteinase-9 in pancreatic cancer cells. Cancer Res 2006;66: 2778-84.
20. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box Ml transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007;67: 8293-300.
21. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 2006;119:2071-7.
22. Gregory PA, Bert AG, Paterson EL, et al. The miK-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
23. Grego-Bessa j, Diez J, Timmerman L, de la Pompa JL. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle 2004;3:718-21.
24. Leong KG, Niessen K, Kulic I, et al. jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007;204:2935-48.
25. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-κB. Lab Invest 2008;88:11-7.
26. Sarkar FH, Li Y, Wang Z, Kong D. NF-kB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008;27:293-319.
27. Harvey SR, Hurd TC, Markus G, et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 2003;9:4935-43.
28. Sahlgren C, Gustafsson MV, jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-indueed tumor cell migration and invasion. Proc Natl Acad Sci USA 2008;105:6392-7.
29. Miele L, Miao H, NickoIoff RJ. Notch signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 2006;6:313-23.
30. Miele L. Notch signaling. Clin Cancer Res 2006;12: 1074-9.
31. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006;5:483-93.
32. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. j Cell Biol 2008;182:315-25.
33. Jang MS, Miao H, Carlesso N, et al. Notch-1 regulates cell death independently of differentiation in murine erythroleukemia cells through multiple apoptosis and cell cycle pathways. J Cell Physiol 2004;199:418-33.
34. Nickoloff Bj, Qin JZ, Chaturvedi V, Denning MF, Bonish B, Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinoeytes through NF-kB and PPAR7. Cell Death Differ 2002;9:842-55.
35. Wang Y, Chan SL, Miele L, et al. involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci U S A 2004;101:9458-62.
36. Fukushima H, Nakao A, Okamoto F, et al. The association of Notch2 and NF-κB accelerates RANKL- induced osteoclastogenesis. Mol Cell Biol 2008;28: 6402-12.
37. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement, of ZEB-1 and ZEB-2. Oncogene 2007;26: 711-24.
38. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH, Inhibition of angiogenesis and invasion by 3,3-diindolyl- methane is mediated by the nuclear factor-kb downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007;67:3310-9.
39. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:122-36.